New digital health platform being launched in partnership with UCSD allows remote physician-monitore...


HOUSTON, TX, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of its new AI-designed virtual clinic platform, NeuroCare®, in collaboration with the University of California, San Diego. This marks the first step in deploying Nexalin’s digital health ecosystem, designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring across critical brain-health indications. This collaboration builds upon Nexalin’s ongoing clinical research relationship with UC San Diego where patient enrollment has begun in trials evaluating Nexalin’s non-invasive Deep Intracranial Frequency Stimulation. This clinical trial marks the official launch of Nexalin’s new Gen-3 HALO™ headset that is now managed and monitored during treatment through the Nexalin NeuroCare® virtual clinic.  Through the NeuroCare virtual clinic platform, patients suffering from Alzheimer’s/dementia, mood disorders (such as depression and anxiety), and military-related conditions, including traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD), will be able to engage with Nexalin’s HALO headset, a powerful frequency-based neurostimulation treatment administered in the privacy of the patients’ home. The NeuroCare platform enables remote treatment monitoring, enhanced privacy, and continuity of care, operating within a subscription-based business model that supports sustainable revenue and long-term patient outcomes.  Nexalin’s virtual clinic is built to dramatically reduce the traditional cost, time barriers and the mental health stigmas associated with psychiatric medication and traditional psychiatric care. Patients can initiate care through a secure remote channel without physically visiting a clinic, thereby eliminating waiting-room delays, reducing physician expenses, and overcoming stigma by offering a private, home-based treatment environment. Physicians are supported by real-time monitoring tools, enabling long-term treatment management and optimizing patients' quality of life.  The NeuroCare digital platform is integrated with Nexalin’s next-generation Gen-3 HALO™ headset, which delivers improved Deep Intracranial Frequency Stimulation (“DIFS™”) in a home-based setting. The integration of the Gen-3 HALO system and NeuroCare creates a complete ecosystem—from remote physician oversight to advanced wearable therapy—for Alzheimer’s/dementia, mood disorders, and TBI/PTSD care. With the virtual clinic serving as the digital hub and the Gen-3 HALO device as the therapeutic delivery mechanism, Nexalin is positioning itself to scale beyond device sales into long-term recurring revenue, clinical data capture, and long-term patient retention. With initial deployment alongside UC San Diego’s clinical infrastructure, Nexalin expects the platform to serve as a cornerstone for scalable, data-driven revenue growth across global markets.  “Today we begin a new chapter in how brain-health therapy is delivered,” said Mark White, CEO of Nexalin. “By launching our Gen-3 HALO neurostimulation system with the NeuroCare AI-designed virtual clinic platform, in partnership with UCSD, we remove the mental health stigma, eliminate access barriers to treatment and lower the cost for patients and physicians alike. Nexalin is committed to building a foundation for a long-term relationship with its clients with recurring monthly subscriptions, long-term treatment adherence, and data-driven outcomes across Alzheimer’s, mood disorders, as well as active military and veteran-care applications. We believe this is a transformative step toward our vision of a full digital health ecosystem for brain-health.”  About Nexalin Technology, Inc.  Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.  FORWARD-LOOKING STATEMENTS  This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.  Contact:  Crescendo Communications, LLCTel: (212) 671-1020Email: NXL@crescendo-ir.com  
            

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New digital health platform being launched in partnership with UCSD allows remote physician-monitore...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Nexalin Technology has launched its AI-designed virtual clinic platform, NeuroCare™, in partnership with UC San Diego. This groundbreaking initiative aims to enhance patient access, reduce costs, and provide continuous care in brain health, potentially driving significant long-term revenue and improved patient outcomes across various critical conditions.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nexalin launches NeuroCare, an AI-designed virtual clinic with UC San Diego.</li><li>Integration with Gen-3 HALO™ headset enhances patient care and monitoring.</li><li>Platform aims to reduce mental health stigma and improve accessibility.</li><li>Subscription model could ensure sustainable revenue growth for Nexalin.</li><li>Nexalin targets substantial markets including Alzheimer’s and PTSD treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>University of California, San Diego (UCSD)</strong>: Collaboration enhances Nexalin&#039;s clinical credibility and potential patient enrollment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it represents a significant strategic initiative in Nexalin&#039;s operations, integrating advanced technology to broaden their service offering and revenue potential.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nexalin&#039;s collaboration with UCSD could significantly enhance credibility and market reach.</li><li>Successful patient trials may lead to accelerated adoption of the NeuroCare platform.</li><li>Introduction of a subscription model could unlock ongoing revenue streams.</li><li>Increased accessibility for mental health treatment may drive exponential patient growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>NeuroCare platform launched on February 5, 2026.</li><li>NeuroCare enables remote monitoring for conditions like Alzheimer’s and PTSD.</li><li>The Gen-3 HALO™ headset is now actively used in clinical trials.</li><li>Nexalin&#039;s virtual clinic aims to reduce mental health stigma and costs.</li><li>NeuroCare operates on a subscription-based business model.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy NXL for long-term growth as new platform may transform revenue model by 2026.</p>
  </section>
</section>


<article>
  <h2>Nexalin Technology Launches NeuroCare®: A Revolutionary AI-Driven Virtual Clinic</h2>
  <p>HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL), a leader in Deep Intracranial Frequency Stimulation (DIFS™), has launched its innovative AI-driven virtual clinic platform, <strong>NeuroCare®</strong>, in partnership with the University of California, San Diego. This initiative represents a significant advancement in digital health, aimed at enhancing patient access, lowering healthcare costs, and providing continuous physician-patient care and monitoring for various critical brain health conditions.</p>

  <section>
    <h3>Details of the NeuroCare® Launch</h3>
    <p>The introduction of NeuroCare® is the first step in utilizing Nexalin’s comprehensive digital health ecosystem. This platform is specifically designed for patients facing challenges related to Alzheimer’s disease, mood disorders such as <em>depression and anxiety</em>, and military-associated conditions, including <strong>traumatic brain injury (TBI)</strong> and <strong>post-traumatic stress disorder (PTSD)</strong>.</p>
    <ul>
      <li><strong>AI-Driven Technology:</strong> NeuroCare® offers AI-supported monitoring of patients’ treatments.</li>
      <li><strong>Home-Based Treatment:</strong> Patients can receive neurostimulation therapy in the privacy of their homes.</li>
      <li><strong>Subscription-Based Model:</strong> The platform will operate on a subscription basis, promoting sustainable revenue and long-term patient outcomes.</li>
    </ul>
  </section>

  <section>
    <h3>Integration with Gen-3 HALO™ Headset</h3>
    <p>NeuroCare® is seamlessly integrated with Nexalin’s next-generation <strong>Gen-3 HALO™ headset</strong>, enhancing the DIFS™ experience in home settings. This combination not only provides remote physician oversight but also facilitates advanced wearable therapy. Nexalin envisions that this model will allow for long-term recurring revenue alongside efficient clinical data capture and patient retention.</p>
  </section>

  <section>
    <h3>Removing Barriers to Mental Health Care</h3>
    <p>Nexalin’s NeuroCare® is designed to address prevalent barriers in mental health care. By eliminating the need for physical clinic visits, the platform reduces waiting-room delays and addresses the stigma often associated with psychiatric treatment. This revolutionary approach to care allows patients to initiate treatment through a secure online channel.</p>
    <p>Physicians are equipped with real-time monitoring tools to manage patient care over longer periods, improving overall quality of life for those involved.</p>
  </section>

  <section>
    <h3>Future Perspectives and CEO Insights</h3>
    <p>“Today we begin a new chapter in how brain health therapy is delivered,” said Mark White, CEO of Nexalin. “The launch of our Gen-3 HALO neurostimulation system alongside the NeuroCare AI-designed virtual clinic platform allows us to remove mental health stigma, eliminate access barriers, and reduce costs for patients and physicians alike.”</p>
    <p>As Nexalin continues to expand its digital health ecosystem, it aims to build long-term client relationships through ongoing subscriptions and effective treatment adherence.</p>
  </section>

  <section>
    <h3>About Nexalin Technology, Inc.</h3>
    <p>Nexalin is at the forefront of developing neurostimulation technologies aimed at combatting the global mental health crisis. Its non-invasive products are designed to deliver relief to those suffering from a variety of mental health issues by penetrating the deep structures of the mid-brain linked to these disorders. The company’s innovation is reflected in products like the Gen-2 15 miliamp neurostimulation device, which has received approval in countries including China, Brazil, Oman, and Israel.</p>
  </section>

  <footer>
    <p>For further information, visit <a href="https://nexalin.com/">Nexalin Technology</a>.</p>
    <p>This announcement contains forward-looking statements regarding Nexalin’s future performance and financial condition. Such statements may involve risks and uncertainties that could cause actual results to differ significantly. For a detailed view of these risks, refer to Nexalin's filings with the Securities and Exchange Commission available at <a href="http://www.sec.gov">www.sec.gov</a>.</p>
    <p>Contact: Crescendo Communications, LLC<br>
    Tel: (212) 671-1020<br>
    Email: NXL@crescendo-ir.com</p>
  </footer>
</article>

Nexalin Technology has launched its AI-designed virtual clinic platform, NeuroCare™, in partnership with UC San Diego. This groundbreaking initiative aims to enhance patient access, reduce costs, and provide continuous care in brain health, potentially driving significant long-term revenue and improved patient outcomes across various critical conditions.

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News